Poly (ADP-ribose) polymerase inhibitor: A new horizon in advanced prostate cancer treatment.

Investig Clin Urol · 2023 · PMC10482661 · PMID 37668196

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A recent update of the PROpel trial showed a trend towards an OS rate that was not statistically significant (42. 1 vs. 34.7 mo; HR=0.81; 95% CI=0.67–1.00) for all comers at data maturity of 47.9% [ 9 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.